Vertaling van "based on strong clinical " (Nederlands → Frans) :

Gleevec/Glivec (USD 3.7 billion, +15% lc), a targeted therapy for certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), sustained solid double-digit growth in 2008 based on strong clinical data and its status as the leading therapy for these and other life-threatening forms of cancer.
Glivec/Gleevec (USD 3,7 milliards, +15% en m. l.), traitement ciblé contre certaines formes de leucémie myéloïde chronique (LMC) et les tumeurs stromales gastro-intestinales (GIST), a conservé une croissance soutenue à deux chiffres, grâce à d’excellents résultats cliniques et à son statut de traitement de pointe pour ces maladies et d’autres formes de cancer souvent fatales.

Novartis increases dividend by 25% based on strong 2008 results from strategic healthcare portfolio
Novartis augmente son dividende de 25% grâce aux excellents résultats de son portefeuille stratégique axé sur la santé

Tekturna/Rasilez (USD 290 million, +104% lc), the first in a new class of medicines known as direct renin inhibitors to treat high blood pressure, has been growing consistently since its launch in 2007 based on positive clinical data demonstrating its prolonged efficacy in lowering blood pressure for more than 24 hours and superiority in clinical trials over ramipril, a leading ACE inhibitor.
Rasilez/Tekturna (USD 290 millions, +104% en m. l.), est le premier d’une nouvelle classe de médicaments, les inhibiteurs directs de la rénine, traitant l’hypertension.

IB (Category IB of US recommendations) : Strongly recommended for implementation and supported by certain experimental, clinical, or epidemiological studies and a strong theoretic rationale. IU : International Unit (virus titration) KVE : kiemvormende eenheden LAF : Laminair Air Flow.
IU : International Unit (virus titration) LAF : Laminair Air Flow.

Exjade (USD 182 million, +7% cc) has continued to expand with strong growth based on new patients, expanded access and increased dosing in the US and key markets around the world.
Exjade (USD 182 millions, +7% tcc) a poursuivi sa forte croissance grâce à de nouveaux malades, à un accès étendu et à une hausse du dosage moyen aux Etats-Unis et dans les principaux marchés du monde entier.

2010 outlook (Barring unforeseen events) Based on the strong first half, we are raising our sales guidance for the full year.
Perspectives 2010 (sauf événements imprévus) Sur la base des excellents résultats enregistrés au premier semestre, nous relevons nos prévisions de chiffre d'affaires sur l'exercice complet.

variation in practice which affects patient outcomes and a strong research base providing evidence of effective practice, guidelines can assist doctors and other health care professionals in making decisions about appropriate and effective care for their patients.
„They are designed to help practitioners assimilate, evaluate and implement the everincreasing amount of evidence and opinion on best current practice. Clinical guidelines are intended as neither cookbook nor textbook but, where there is evidence of variation in practice which affects patient outcomes and a strong research base providing evidence of effective practice, guidelines can assist doctors and other health care professionals in making decisions about appropriate and effective care for their patients.

More than 30,000 people were enrolled in A (H1N1) pandemic vaccine clinical trials, while three different technology platforms (traditional egg-based, cell-culture-based and MF-59 adjuvanted vaccines) received regulatory approvals to maximize the vaccine supply.
Plus de 30 000 personnes ont été engagées dans les essais cliniques de ce vaccins, tandis que trois plateformes faisant appel à des technologies différentes (traditionnelle à base d’œufs, culture cellulaire et adjuvantation par MF-59) ont été autorisées afin de maximaliser les quantités livrées.

88 tot 95% van de gevallen op basis van population-based studies en bij 70 tot 80% van de gevallen op basis van clinic-based studies.
80% des cas sur la base d'études cliniques.

Valturna – a single-pill combination of Tekturna/Rasilez and Diovan (valsartan) – gained US regulatory approval in September based on clinical data showing this medicine offers significantly higher blood pressure reduction than either valsartan or aliskiren alone.
Valturna, un comprimé associant Rasilez/Tekturna et Diovan (valsartan), a obtenu, en septembre, son autorisation de mise sur le marché aux Etats-Unis. Cette décision s'est appuyée sur des données cliniques montrant que ce médicament provoque une baisse nettement plus importante de la pression sanguine que valsartan ou aliskiren seuls.